IDEAYA Biosciences, Inc. (IDYA) Form 8-K — Aug 4, 2026
IDEAYA Biosciences announced that its registrational Phase 2/3 OptimUM-02 trial evaluating darovasertib in metastatic uveal melanoma met its primary endpoint of progression-free survival. Patients treated with the darovasertib combination demonstrated a median PFS of 6.9 months versus 3.1 months in the control arm, representing a statistically significant improvement with a hazard ratio of 0.42. Based on these results, the company is proceeding with a New Drug Application submission under the FDA's real-time oncology review program, with completion targeted for the second half of 2026.
Key figures
- Cash Position
- 1242889000
- Collaboration Revenue
- 8857000
- P value
- <0.0001
- Ga expenses
- 22500000
- Rd expenses
- 108700000
- Hazard ratio
- 0.42
- Pfs months control
- 3.1
- Pfs months treatment
- 6.9
- Net proceeds offering
- 323400000
Price after filing
Close on the filing date to close N calendar days later (from $36.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.